Case report

**Pulmonary cannonballs in a patient with Acquired Immunodeficiency Syndrome (AIDS)**

Miranda McGhee^a,*, Dante Paolo Melendez-Lecca^b, Nelson Iván Agudelo Higuita^a

^a Section of Infectious Diseases, Department of Internal Medicine, University of Oklahoma Health Sciences Center, 800 Stanton L. Young Blvd., Suite 7300, Oklahoma City, OK, 73104, United States

^b Division of Infectious Diseases, 30 N1900 E, 48319, Salt Lake City, UT, 84132, United States

**A R T I C L E   I N F O**

Article history:
Received 13 April 2021
Received in revised form 15 July 2021
Accepted 15 July 2021

Keywords:
*Pneumocystis jirovecii* pneumonia
Cannonballs
HIV
AIDS

**A B S T R A C T**

*Pneumocystis jirovecii* pneumonia (PJP) remains one of the most common and life-threatening complications in patients with AIDS. PJP typically presents subacutely with a dry cough, shortness of breath with exertion, fever, and bilateral ground-glass opacities on imaging. However, atypical imaging findings have been reported including cysts, isolated lymphadenopathy, and small to large nodules. This case highlights the importance of considering unusual presentations of a relatively common entity in order to prevent delays in diagnosis and treatment.

© 2021 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

**Introduction**

*Pneumocystis jirovecii* pneumonia (PJP) is an opportunistic infection cause by the unicellular fungus, *Pneumocystis jirovecii*. It gained global recognition in the early 1980s as one of the most common and the first defining illness associated with acquired immunodeficiency syndrome (AIDS) in Europe and the Americas. The introduction of highly active antiretroviral therapy in the mid 1990s coupled with the implementation of effective, affordable, and safe prophylactic measures for those at risk resulted in a substantial decline in cases [1]. Despite the effectiveness of chemoprophylaxis and antiretroviral therapy, PJP remains one of the most common human immunodeficiency virus (HIV)-related opportunistic infections.

*Pneumocystis* spp. exists in 3 different morphological forms: cyst, trophozoite, and sporozoite. The organism is transmitted from human to human via the airborne route, with those with asymptomatic colonization serving as reservoirs [1,2]. In patients with HIV, PJP typically presents subacutely with a dry cough, shortness of breath with exertion, fever, and bilateral ground-glass opacities on imaging. However, unusual imaging findings have been reported including cysts, isolated lymphadenopathy, and small to large nodules [3]. This case highlights the importance of considering atypical presentations of a relatively common entity in order to prevent delays in diagnosis and treatment.

**Case**

A 50-year-old female with a history of HIV/AIDS (CD4 + 0 cells/μL, viral load 9,840 copies/mL) diagnosed in 2007 and not on antiretroviral therapy for the last 18 months presented to the hospital for the evaluation of a one-week history of dry cough and one-day history of hemoptysis. Trimethoprim-sulfamethoxazole (TMP/SMX) had been provided by an urgent care clinic three days before admission without improvement. The patient also had history of *Pneumocystis pneumonia* and progressive disseminated histoplasmosis diagnosed in 2007. She denied having other opportunistic infections in the past or other medical problems since stopping antiretroviral therapy 18 months ago. The day she first presented to the hospital with these symptoms will be defined as “day 0” in this report.

On exam, blood pressure was 116/65 mmHg, pulse was 123 beats per minute, temperature 36.9 °C and respiratory rate of 24 breaths per minute. She appeared malnourished and chronically ill. She had a healed tracheostomy scar and the lung exam was significant for bibasilar rales (worse on the right) with hemoptysis on a tissue at bedside. A complete blood count was normal with the exception of microcytic anemia with a hemoglobin of 10 g/dL. A complete metabolic panel was within normal limits. Venous blood gas analysis showed respiratory alkalosis with low partial pressure of carbon dioxide at 38 mm Hg (reference range 41–47 mm Hg). The urinalysis was normal and the urine drug screen was negative.

The initial microbiologic evaluation consisted of a sputum culture which showed normal respiratory flora. BioFire Film Array showed *Chlamydophila pneumoniae*. A chest x-ray noted “multiple large lung masses in bilateral lower lobes.” A computed...
tomography (CT) chest angiogram showed: “No evidence of pulmonary embolism. Large posterior right lower lobe heterogeneous lesion with several foci of gas. Other bilateral pulmonary masses. Enlarged subcarinal and left lower paratracheal lymph nodes” (Fig. 1). Additional testing included a negative serum cryptococcal antigen and urine Streptococcus pneumoniae antigen. Three sputum samples were collected and submitted for acid fast bacilli smear and cultures with negative results. The QuantiFERON gold gamma interferon release assay was also negative. A direct fluorescence antibody (DFA) staining for P. jiroveci in expectorated sputum was negative. Urine and serum histoplasma antigens were negative. The plasma Epstein-Barr virus DNA viral load was 5,600 IU/mL (reference range 0 IU/mL).

The patient was started on levofloxacin for presumable Chlamydia pneumoniae pneumonia and prophylactic TMP/SMX. There was a lack of improvement in dry cough and associated hemoptysis on day +4 of admission.

On day +4 of hospital admission, she underwent a computed tomography guided biopsy of the large right lung mass. The Gram stain showed 2–5 white blood cells and no organisms. Acid fast bacilli smears and culture of the tissue were negative. Fungal and bacterial cultures were also negative. The pathology report was: “Positive for fungal organisms. Special stain revealed scattered individual 4–6 μm round structures consistent with yeast. No definitive budding identified. The cytomorphology of these organisms is consistent with Pneumocystis jiroveci” (Fig. 2).

The patient was started on treatment dosing of TMP/SMX. A repeat DFA staining for P. jiroveci from induced sputum was positive. Serum test for 1–3 B-D-glucan (Fungitell) was positive at 133 pg/mL (reference range 0–80 pg/mL). Antiretroviral therapy with abacavir sulfate, lamivudine, dolutegravir, and tenofovir disoproxil fumarate was started based on previous HIV genotypes. She was seen in clinic at the end of the 21-day treatment course with TMP/SMX and reported complete resolution of cough and hemoptysis. A repeat CT of the chest was ordered but the patient has missed her follow-up appointments.

Discussion

Pneumocystis was initially considered a protozoan based on several morphologic features that included the lack of ergosterol in the cell membrane, susceptibility to anti-protozoan drugs, and lack of growth on routine laboratory media [1,4,5]. It was later classified as an ascomycetous fungi based on sequencing homology demonstrated by molecular studies [5]. Phenotypic and genetically distinct Pneumocystis species has been described in a number of
mammalian species. These distinct species have strict host predilections that are not transmissible to other mammalian hosts [6–8].

Three forms of the organism have been identified in humans and animals—cyst, trophozoite, and the sporozoite or intracytic form. All forms have been observed within the lungs, with the predominating morphology being the trophic form in active infection [9]. The diagnosis is based on the detection of the different forms by tinctorial staining, direct fluorescent antibody (DFA) staining, or polymerase chain reaction (PCR). DFA staining detects both trophic and cystic forms. Data comparing expectorated sputum versus induced sputum with hypertonic saline for the diagnosis of Pneumocystis pneumonia is limited. In those with AIDS, increasing sensitivity is noted with induced sputum, bronchoalveolar lavage, and transbronchial biopsy, respectively [10]. In those with immunocompromise conditions other than AIDS, the diagnostic yield of staining and microscopy is reduced due to decreased organism burden [11].

One distinctive feature is the presence of cholesterol in the Pneumocystis cell membrane, instead of ergosterol, the major binding site of amphotericin B [9]. Azoles target sterol synthesis by inhibiting the cytochrome P450 enzyme, 14α-lanosterol demethylase, which facilitates a key step in the conversion of lanosterol to ergosterol, rendering azoles an ineffective treatment for Pneumocystis [12]. The current first line of treatment and prophylaxis for Pneumocystis pneumonia is TMP-SMX. TMP-SMX inhibits the enzyme dihydropyrimidinase synthase (DHPS) impairing folate synthesis.

Although improvements in the use of prophylactic interventions and access to antiretroviral therapy have led a decrease in its incidence, Pneumocystis jirovecii pneumonia remains one of the most common and life-threatening opportunistic infections in patients with AIDS [13]. The typical imaging finding is that of diffuse and bilateral infiltrates. Rare chest imaging findings include cystic pulmonary lesions, miliary nodules, larger solitary nodules, and cavitary lesions [3,14,15]. Atypical imaging presentations of P. jirovecii pneumonia are thought to occur in the setting of distortion of the normal lung architecture related to prior infections [16].

Pulmonary nodules or masses are infrequent, representing less than 5% of all P. jirovecii presentations, and typically represent granulomatous formation [15,17]. These are usually encountered early in the course of HIV infection or in those on antiretroviral therapy, when patients are able to mount a granulomatous response without the development of necrosis and cavitation [13,18–20]. Solid nodular pulmonary lesions due to PJP is an exceedingly rare presentation leading to delays in diagnosis. Granulomatous PJP should be considered in the differential diagnosis of pulmonary nodules with the appearance of cannonballs in immunocompromised individuals.

Funding

No funding was received for this publication.

Ethical approval

None required.

Consent

None necessary.

Author contributions

Miranda McGhee: Writing – Original draft preparation, Visualization. Nelson Iván Agudelo Higuina: Writing – Review and Editing, Supervision. Dante Paolo Melendez-Lecca: Writing – Review and Editing.

Acknowledgement

Authors acknowledge Dr. Rufei Lu for assistance in pathologic imaging acquisition.

References

[1] Sokulska M, Kicia M, Woselowska M, Hendrich AB. Pneumocystis jiroveci – from a commensal to pathogen: clinical and diagnostic review, Parasitol Res 2015;114(10):3577–85.
[2] Hughes WT. Pneumocystis carinii. In: Baron S, editor. Medical microbiology. th Galveston (TX): Chapter 85.
[3] Kim B, Kim J, Paik S, Pai H. Atypical presentation of Pneumocystis jiroveci Infection in HIV infected patients: Three Different Manifestations. J Korean Med Sci 2018;33(15):e115.
[4] Stringer JR. Pneumocystis carinii: what is it, exactly? Clin Microbiol Rev 1996;9(4):89–98.
[5] Edman JC, Kovacs JA, Masur H, Santi DV, Elwood HJ, Sogin ML. Ribosomal RNA sequence shows Pneumocystis carinii to be a member of the fungi. Nature 1988;334(6182):519–22.
[6] Gigliotti F, Stokes DC, Cheatham AB, Davis DS, Hughes WT. Development of murine monoclonal antibodies to Pneumocystis carinii. J Infect Dis 1986;154(2):315–22.
[7] Sinclair K, Wakefield AE, Banerji S, Hopkin JM. Pneumocystis carinii organisms derived from rat and human hosts are genetically distinct. Mol Biochem Parasitol 1991;45(1):183–4.
[8] Gigliotti F, Harmsen AG, Haidaris GC, Haidaris PJ. Pneumocystis carinii is not universally transmissible between mammalian species. Infect Immun 1993;61(7):2886–90.
[9] Kaneshiro ES. Sterol biosynthesis in Pneumocystis: unique steps that define unique targets. Drug Resist Updates 2002;5(6):259–68.
[10] Pitchencuk AE, Ganjei P, Torres A, Evans DA, Rubin E, Baier H. Sputum examination for the diagnosis of Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. Am Rev Respir Dis 1986;133(2):226–9.
[11] Limper AH, Offord RT, Smith TF, Martin 2nd WJ. Pneumocystis carinii pneumonia. Differences in lung parasite number and inflammation in patients with and without AIDS. Am Rev Respir Dis 1989;140(5):1204–9.
[12] Porollo A, Meller J, Joshi Y, Jaiswal V, Smulian AG, Cushion MT. Analysis of current antifungal agents and their targets within the Pneumocystis carinii genome.Curr Drug Targets 2012;13(12):1575–85.
[13] Boiselle PM, Crans Jr. CA, Kaplan MA. The changing face of Pneumocystis carinii pneumonia in AIDS patients. Am J Roentgenol 1999;172(5):1301–9.
[14] Kim HS, Shin KE, Lee JH. Single nodular opacity of granulomatous pneumocystis jiroveci pneumonia in an asymptomatic lymphoma patient. Korean J Radiol 2015;16(2):440–3.
[15] Hartel PH, Shilo K, Klassen-Fischer M, Neaffe R, Ozbudak I, Calvin J, et al. Granulomatous reaction to pneumocystis jiroveci: clinico-pathologic review of 20 cases. Am J Surg Pathol 2010;34(5):730–4.
[16] Block BL, Mehta T, Ortiz GM, Ferris SP, Vu TH, Huang L, et al. Unusual radiographic presentation of Pneumocystis Pneumonia in a patient with AIDS. Case Rep Infect Dis 2017:2017:3183525.
[17] Travis WD, Pittaluga S, Lipschik GY, Ognibene FP, Suffredini AF, Masur H, et al. Atypical pathologic manifestations of Pneumocystis carinii pneumonia in the acquired immune deficiency syndrome. Review of 123 lung biopsies from 76 patients with emphasis on cysts, vascular invasion, vasculitis, and granulomas. Am J Surg Pathol 1990;14(7):615–25.
[18] Klein JS, Warnock M, Webb WR, Gamsu G. Cavitating and noncavitating granulomas in AIDS patients with Pneumocystis pneumonia. Am J Roentgenol 1989;152(4):753–4.
[19] Marchiori E, Muller NL, Soares Souza Jr. A, Escuissato DL, Gasparetto EL, Franquet T. Pulmonary disease in patients with AIDS: high-resolution CT and pathologic findings. Am J Roentgenol 2005;184(3):757–64.
[20] Hartz JW, Grinsinger KR, Schary M, Muis HR. Granulomatous pneumocystosis presenting as a solitary pulmonary nodule. Arch Pathol Lab Med 1985;109 (5):466–9.